Christopher P. Day

The NAFLD fibrosis score

Paul Angulo, Jason M. Hui, Giulio Marchesini et al. · Hepatology · 2007 · 3.2K citations · Full text

Medicine, Internal Medicine, Pathology +17

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Chris Estes, Quentin M. Anstee, M. Arias et al. · Journal of Hepatology · 2018 · 2K citations · Full text

Medicine, Health Sciences, Epidemiologic Methods +16

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Guruprasad P. Aithal, Christopher P. Day, Patrick Kesteven et al. · The Lancet · 1999 · 1.2K citations

Medicine, Pharmacokinetics, Pharmacology +12

QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.

Christopher P. Day, Janet M. McComb, R. W. F. Campbell · Heart · 1990 · 1.2K citations · Full text

Medicine, Cardiology, Pharmacology +14

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management

Stuart McPherson, Timothy Hardy, Elsbeth Henderson et al. · Journal of Hepatology · 2014 · 1K citations · Full text

Medicine, Internal Medicine, Pathology +17